ARS Pharmaceuticals, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
This is ARS Pharmaceuticals' routine Q2 2026 10-Q quarterly report filing submitted to the SEC on August 13, 2026, covering the period ended June 30, 2026. The filing consists of standard regulatory documents (77 documents total) including financial statements, officer certifications, and XBRL data files. No specific financial metrics, material transactions, counterparties, or business changes are disclosed in the header/metadata provided.
Why this rating
Routine quarterly SEC disclosure; no material transaction, guidance change, or operational event stated. Standard periodic filing.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.